These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20196945)

  • 41. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
    Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
    J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular methods in the diagnosis and management of chronic hepatitis B.
    Vivekanandan P; Singh OV
    Expert Rev Mol Diagn; 2010 Oct; 10(7):921-35. PubMed ID: 20964611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
    Chen JY; Wang LW; Sun XM; Gong ZJ
    Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay.
    Lindh M; Hannoun C; Malmström S; Lindberg J; Norkrans G
    J Clin Microbiol; 2006 Jul; 44(7):2587-9. PubMed ID: 16825388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distribution of hepatitis B virus genotypes among patients with chronic infection.
    Ribeiro NR; Campos GS; Angelo AL; Braga EL; Santana N; Gomes MM; Pinho JR; De Carvalho WA; Lyra LG; Lyra AC
    Liver Int; 2006 Aug; 26(6):636-42. PubMed ID: 16842318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of antiviral resistance in patients with chronic hepatitis B.
    Locarnini S; Hatzakis A; Heathcote J; Keeffe EB; Liang TJ; Mutimer D; Pawlotsky JM; Zoulim F
    Antivir Ther; 2004 Oct; 9(5):679-93. PubMed ID: 15535405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Profile, spectrum and significance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China.
    You J; Sriplung H; Chongsuvivatwong V; Geater A; Zhuang L; Huang JH; Chen HY; Yu L; Tang BZ
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):271-9. PubMed ID: 18522881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The influence of HBV genotypes on the therapeutic effects of lamivudine in chronic hepatitis B patients].
    Tan WT; Deng GH; Wang YM; Dan YJ; Kuang XM
    Zhonghua Gan Zang Bing Za Zhi; 2008 Jul; 16(7):540-1. PubMed ID: 18647538
    [No Abstract]   [Full Text] [Related]  

  • 52. Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection.
    Rodriguez-Frias F; Jardi R; Buti M; Schaper M; Hermosilla E; Valdes A; Allende H; Martell M; Esteban R; Guardia J
    J Viral Hepat; 2006 May; 13(5):343-50. PubMed ID: 16637866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba.
    Liu CJ; Chen PJ; Lai MY; Chen TC; Wang HY; Huang WL; Kao JH; Chen DS
    Antivir Ther; 2004 Dec; 9(6):895-903. PubMed ID: 15651748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of antiviral therapy on the cellular immune response in patients with chronic hepatitis B.
    Luo G; Feng X; Huang Y; Yi T; Wang D; Guo X; Yan H; Zhang G
    Mol Med Rep; 2015 Feb; 11(2):1284-91. PubMed ID: 25371014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
    Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
    J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection.
    Chan HL; Tsang SW; Liew CT; Tse CH; Wong ML; Ching JY; Leung NW; Tam JS; Sung JJ
    Am J Gastroenterol; 2002 Feb; 97(2):406-12. PubMed ID: 11866280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection.
    Venegas M; Alvarado-Mora MV; Villanueva RA; Rebello Pinho JR; Carrilho FJ; Locarnini S; Yuen L; Brahm J
    J Med Virol; 2011 Sep; 83(9):1530-6. PubMed ID: 21739442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
    Hermans LE; Svicher V; Pas SD; Salpini R; Alvarez M; Ben Ari Z; Boland G; Bruzzone B; Coppola N; Seguin-Devaux C; Dyda T; Garcia F; Kaiser R; Köse S; Krarup H; Lazarevic I; Lunar MM; Maylin S; Micheli V; Mor O; Paraschiv S; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Simon F; Stanojevic M; Stene-Johansen K; Tihic N; Trimoulet P; Verheyen J; Vince A; Weis N; Yalcinkaya T; Lepej SZ; Perno C; Boucher CA; Wensing AM;
    J Infect Dis; 2016 Jan; 213(1):39-48. PubMed ID: 26136470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The spontaneous YMDD mutation rate in chronic hepatitis B patients].
    Min XC; Miao XH; Zhao SM; Zhao KK; Yang DG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):887-90. PubMed ID: 20038327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.